Journal article
Optimizing risk factors to guide COST‐effective use of palivizumab in KOREAN infants
Abstract
BACKGROUND: Korean infants born at 32-35 weeks gestational age (wGA) receive palivizumab prophylaxis to prevent respiratory syncytial virus hospitalization (RSVH) if they are born during the RSV season and have a sibling. The aim of this study was to evaluate the impact of using the International Risk Scoring Tool (IRST) to target prophylaxis in Korea.
METHODS: The IRST includes 3 risk factors: birth 3 months before to 2 months after the RSV …
Authors
Kang J; Carbonell‐Estrany X; Paes B; Rodgers‐Gray B; Fullarton J; Tarride J; Yang H; Chang YS; Keary I
Journal
Pediatrics International, Vol. 67, No. 1,
Publisher
Wiley
Publication Date
1 2025
DOI
10.1111/ped.70021
ISSN
1328-8067